Related Experiment Video
Updated: Jul 8, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
Published on: January 7, 2019
Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder
Richard C Shelton1, George I Papakostas
1Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN, USA. richard.shelton@vanderbilt.edu
Objective:
Atypical antipsychotics (AAPs) have been hypothesized to be beneficial in treatment-resistant depression (TRD). This paper will review a biochemical rationale and will summarize the data regarding the effectiveness of AAPs in TRD.
Method:
Studies were identified using searches of Pubmed/Medline, EMBase and the Cochrane databases by cross-referencing the term 'depression' with each of the six AAPs.
Results:
After initial positive, short case reports and clinical trials, larger studies failed to show the effectiveness of AAPs combined with antidepressants for TRD. More recently, larger scale clinical trials have supported the effectiveness of at least some of these medications. While AAPs have gained in popularity for TRD, there are nagging concerns regarding risks such as metabolic syndrome and tardive dyskinesia.
Conclusion:
The existing research provides some support for the beneficial effects of AAPs when combined with SSRI's in TRD. These medications pose significant risks that must be considered in their use.
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Antidepressant Drugs: Overview
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Psychosis and Antipsychotic Drugs: Overview
Psychosis: Goals of Pharmacotherapy
Drug Therapy
Antianxiety Medications